Takhzyro is a medicine used to prevent attacks of hereditary angioedema in patients aged 2 years and over.
Patients with angioedema have rapid swelling under the skin in areas such as the face, throat, arms and legs. Attacks of hereditary angioedema can be life threatening when the swelling around the throat presses against the airway.
Takhzyro contains the active substance lanadelumab.
Takhzyro : EPAR - Medicine overview (PDF/117.22 KB) (updated)
First published: 17/12/2018
Last updated: 22/11/2023
Takhzyro : EPAR - Risk-management-plan summary (PDF/43.51 KB) (new)
First published: 22/11/2023
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Takeda Pharmaceuticals International AG Ireland Branch
|Date of issue of marketing authorisation valid throughout the European Union||
Block 2 Miesian Plaza
15/11/2023 Takhzyro - EMEA/H/C/004806 - X/0034/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Other hematological agents
TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.